BRPI0913214A2 - sistema de fornecimento de drogas transdérmico estabilizado - Google Patents

sistema de fornecimento de drogas transdérmico estabilizado

Info

Publication number: BRPI0913214A2
Authority: BR; Brazil
Prior art keywords: delivery system; drug delivery; transdermal drug; stabilized; stabilized transdermal
Prior art date: 2008-05-30

Application number

BRPI0913214A

Other languages

English (en)

Inventor

Jiashang Tang

Original Assignee

Mylan Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-30

Filing date

2009-05-29

Publication date

2016-01-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41380695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913214(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-29 Application filed by Mylan Lab Inc filed Critical Mylan Lab Inc

2016-01-19 Publication of BRPI0913214A2 publication Critical patent/BRPI0913214A2/pt

2022-05-17 Publication of BRPI0913214B1 publication Critical patent/BRPI0913214B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0913214-7A 2008-05-30 2009-05-29 Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo BRPI0913214B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5745508P	2008-05-30	2008-05-30
US61/057,455		2008-05-30
PCT/US2009/045739 WO2009158120A2 (en)	2008-05-30	2009-05-29	Stabilized transdermal drug delivery system

Publications (2)

Publication Number	Publication Date
BRPI0913214A2 true BRPI0913214A2 (pt)	2016-01-19
BRPI0913214B1 BRPI0913214B1 (pt)	2022-05-17

Family

ID=41380695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0913214-7A BRPI0913214B1 (pt)	2008-05-30	2009-05-29	Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo

Country Status (11)

Country	Link
US (2)	US9226902B2 (pt)
EP (1)	EP2299989B1 (pt)
JP (2)	JP5695562B2 (pt)
KR (1)	KR101590209B1 (pt)
CN (1)	CN102099020B (pt)
AU (2)	AU2009262871B2 (pt)
BR (1)	BRPI0913214B1 (pt)
CA (1)	CA2726136C (pt)
MX (1)	MX2010012989A (pt)
NZ (1)	NZ589542A (pt)
WO (1)	WO2009158120A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2726136C (en) *	2008-05-30	2016-11-01	Mylan Laboratories, Inc.	Stabilized transdermal drug delivery system
WO2011034323A2 (en) *	2009-09-16	2011-03-24	Samyang Corporation	Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
ES2679800T3 (es) *	2009-12-22	2018-08-31	Lts Lohmann Therapie-Systeme Ag	Polivinilpirrolidona para la estabilización de una dispersión sólida de la forma no cristalina de rotigotina
EP2884969A1 (en) *	2012-08-15	2015-06-24	Dow Corning Corporation	Multi - layer transdermal drug delivery system
TW201431570A (zh)	2012-11-22	2014-08-16	Ucb Pharma Gmbh	用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) *	2013-05-08	2016-07-28	株式会社ケイ・エムトランスダーム	貼付剤
CN105358139B (zh)	2013-07-03	2020-10-16	Lts罗曼治疗方法有限公司	具有电子元件的经皮治疗系统
WO2015025767A1 (ja) *	2013-08-21	2015-02-26	久光製薬株式会社	貼付剤
MX369030B (es) *	2014-01-22	2019-10-25	4P Therapeutics	Sistemas transdérmicos restrictivos de abuso y mal uso.
EP3145502B1 (en)	2014-05-20	2022-07-06	LTS Lohmann Therapie-Systeme AG	Transdermal delivery system containing rotigotine
JP6895755B2 (ja)	2014-05-20	2021-06-30	エルテーエスローマンテラピー−ジステーメアーゲー	経皮送達システムにおける活性薬剤の放出を調節するための方法
EP3145504B1 (en)	2014-05-20	2023-07-26	LTS Lohmann Therapie-Systeme AG	Transdermal delivery system including an interface mediator
CA2962080A1 (en) *	2014-09-24	2016-03-31	Pain Therapeutics, Inc.	4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en)	2014-12-23	2018-07-03	Barr Laboratories, Inc.	Transdermal dosage form
US9650338B1 (en)	2016-07-29	2017-05-16	VDM Biochemicals, Inc.	Opioid antagonist compounds and methods of making and using
KR102506333B1 (ko)	2016-12-20	2023-03-06	에르테에스 로만 테라피-시스테메 아게	아세나핀을 함유하는 경피흡수 치료 시스템
MX382132B (es)	2016-12-20	2025-03-13	Lts Lohmann Therapie Systeme Ag	Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno
KR102241892B1 (ko)	2017-01-25	2021-04-20	한국전자기술연구원	백스캐터 통신을 위한 데이터 부호화 방법 및 이를 위한 장치
US11179469B2 (en)	2017-04-28	2021-11-23	Nitto Denko Corporation	Transdermal absorption preparation
CN110799180A (zh)	2017-06-26	2020-02-14	罗曼治疗系统股份公司	含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
WO2019243432A1 (en)	2018-06-20	2019-12-26	Lts Lohmann Therapie-Systeme Ag	Transdermal therapeutic system containing asenapine
PL3810100T3 (pl)	2018-06-20	2025-05-12	Lts Lohmann Therapie-Systeme Ag	Transdermalny system terapeutyczny zawierający asenapinę
WO2020166298A1 (ja) *	2019-02-15	2020-08-20	久光製薬株式会社	ロチゴチン安定化方法
CA3133952A1 (en) *	2019-03-19	2020-09-24	Nobelpharma Co., Ltd.	Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability
WO2020243506A1 (en) *	2019-05-31	2020-12-03	Kindeva Drug Delivery	Removable film-forming gel compositions featuring adhesion promoters
PT3854388T (pt) *	2020-01-24	2023-12-11	Luye Pharma Switzerland Ag	Sistema terapêutico transdérmico com o princípio ativo rotigotina e pelo menos um adesivo de silicone não resistente a aminas
TW202228688A (zh) *	2020-08-31	2022-08-01	日商耐貝醫藥股份有限公司	用於神經退化性疾病之症狀緩解或治療之貼附劑
CN112891324A (zh) *	2021-01-19	2021-06-04	北京亚宝生物药业有限公司	一种透皮贴剂
KR102363479B1 (ko) *	2021-03-12	2022-02-15	환인제약 주식회사	로티고틴 함유 경피 흡수 제제
EP4351536A1 (en) *	2021-06-06	2024-04-17	Starton Therapeutics, Inc.	Transdermal drug delivery systems for administration of a therapeutically effective amount of lenalidomide and other immunomodulatory agents
CN116270575A (zh) *	2021-08-16	2023-06-23	乐明药业(苏州)有限公司	一种含有氟比洛芬的药物组合物与贴剂
CN120417892A (zh) *	2022-12-26	2025-08-01	丸仁制药株式会社	透皮吸收制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2920500A1 (de) *	1979-05-21	1980-11-27	Boehringer Sohn Ingelheim	Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) *	1982-02-10	1983-08-18	Boehringer Ingelheim KG, 6507 Ingelheim	Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
JPS60169414A (ja) *	1984-02-14	1985-09-02	Taisho Pharmaceut Co Ltd	経皮吸収剤
US4797284A (en) *	1986-03-12	1989-01-10	Merck & Co., Inc.	Transdermal drug delivery system
US4880633A (en) *	1986-03-12	1989-11-14	Merck & Co., Inc.	Transdermal drug delivery system
US4832953A (en) *	1987-08-13	1989-05-23	Alza Corporation	Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5656286A (en)	1988-03-04	1997-08-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9021674D0 (en) *	1990-10-05	1990-11-21	Ethical Pharma Ltd	Transdermal device
US5164190A (en) *	1990-12-11	1992-11-17	Theratech, Inc.	Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
IT1253265B (it) *	1991-11-25	1995-07-14	Rotta Research Lab	Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5494680A (en) *	1993-12-08	1996-02-27	Minnesota Mining And Manufacturing Company	Transdermal delivery device
JP4102901B2 (ja) *	1994-09-14	2008-06-18	スリーエムカンパニー	経皮薬剤導入用マトリックス
US5662928A (en) *	1995-04-21	1997-09-02	Ciba-Geigy Corporation	Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
KR970009795A (ko) *	1995-08-30	1997-03-27	이웅열	경피투여용 첩부제 조성물
US5906830A (en) *	1995-09-08	1999-05-25	Cygnus, Inc.	Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US6238700B1 (en) *	1995-12-01	2001-05-29	Alza Corporation	Method for preventing crystal formation in a dispersion of a liquid in a matrix
ES2162124T3 (es) *	1995-12-01	2001-12-16	Alza Corp	Metodo mejorado para evitar la formacion de cristales en una dispersion de un liquido en una matriz.
DE19548332A1 (de) *	1995-12-22	1997-07-10	Rotta Res Bv	Hormonpflaster
US6623763B2 (en) *	1996-01-08	2003-09-23	Lts Lohmann Therape-System Ag	Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) *	1996-03-21	1999-02-09	China-America Technology Corp. (Ctc)	Manufacturing method of programmable transdermal therapeutic system
DE19629468A1 (de)	1996-07-11	1998-01-15	Schering Ag	Transdermale therapeutische Systeme
US20040018241A1 (en) *	1997-09-26	2004-01-29	Noven Pharmaceuticals, Inc.	Bioadhesive compositions and methods for topical administration of active agents
DE19906152B4 (de) *	1999-02-10	2005-02-10	Jenapharm Gmbh & Co. Kg	Wirkstoffhaltige Laminate für Transdermalsysteme
DE10060550C1 (de) *	2000-12-06	2002-04-18	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
WO2003034961A1 (en) *	2001-10-23	2003-05-01	Euro-Celtique, S.A.	Terazosin transdermal device and methods
US8246980B2 (en) *	2002-07-30	2012-08-21	Ucb Pharma Gmbh	Transdermal delivery system
DE10261696A1 (de)	2002-12-30	2004-07-15	Schwarz Pharma Ag	Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
KR100682729B1 (ko) *	2004-06-15	2007-02-15	(주)아모레퍼시픽	신규 경피흡수제제 및 그 제조방법
DE102004062182B4 (de) *	2004-12-20	2007-06-06	Bayer Schering Pharma Ag	Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20060188558A1 (en) *	2005-02-18	2006-08-24	Mylan Technologies, Inc.	Transdermal systems having control delivery system
WO2007077741A1 (ja) *	2005-12-28	2007-07-12	Hisamitsu Pharmaceutical Co., Inc.	経皮吸収型製剤
US20080226698A1 (en) *	2007-03-16	2008-09-18	Mylan Technologies, Inc.	Amorphous drug transdermal systems, manufacturing methods, and stabilization
RU2492858C2 (ru) *	2007-04-11	2013-09-20	Омерос Корпорейшн	Композиции и способы профилактики и лечения зависимостей
CA2726136C (en) *	2008-05-30	2016-11-01	Mylan Laboratories, Inc.	Stabilized transdermal drug delivery system
EP2675434A1 (en)	2011-02-17	2013-12-25	F.Hoffmann-La Roche Ag	A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion

2009
- 2009-05-29 CA CA2726136A patent/CA2726136C/en active Active
- 2009-05-29 JP JP2011511876A patent/JP5695562B2/ja active Active
- 2009-05-29 AU AU2009262871A patent/AU2009262871B2/en active Active
- 2009-05-29 US US12/475,390 patent/US9226902B2/en active Active
- 2009-05-29 KR KR1020107029551A patent/KR101590209B1/ko active Active
- 2009-05-29 US US12/994,918 patent/US20110182949A1/en not_active Abandoned
- 2009-05-29 MX MX2010012989A patent/MX2010012989A/es active IP Right Grant
- 2009-05-29 CN CN2009801289266A patent/CN102099020B/zh active Active
- 2009-05-29 WO PCT/US2009/045739 patent/WO2009158120A2/en not_active Ceased
- 2009-05-29 BR BRPI0913214-7A patent/BRPI0913214B1/pt active IP Right Grant
- 2009-05-29 NZ NZ589542A patent/NZ589542A/xx not_active IP Right Cessation
- 2009-05-29 EP EP09770655.0A patent/EP2299989B1/en active Active
2014
- 2014-11-17 JP JP2014232586A patent/JP2015083569A/ja active Pending
2016
- 2016-04-08 AU AU2016202212A patent/AU2016202212B2/en active Active

Also Published As

Publication number	Publication date
CA2726136C (en)	2016-11-01
AU2009262871A1 (en)	2009-12-30
MX2010012989A (es)	2011-04-27
EP2299989A2 (en)	2011-03-30
US20090299304A1 (en)	2009-12-03
EP2299989B1 (en)	2019-01-02
AU2009262871B2 (en)	2016-04-14
CA2726136A1 (en)	2009-12-30
EP2299989A4 (en)	2013-11-13
US9226902B2 (en)	2016-01-05
CN102099020A (zh)	2011-06-15
JP2015083569A (ja)	2015-04-30
KR20110025931A (ko)	2011-03-14
JP5695562B2 (ja)	2015-04-08
AU2016202212A1 (en)	2016-05-12
KR101590209B1 (ko)	2016-02-01
US20110182949A1 (en)	2011-07-28
NZ589542A (en)	2012-10-26
WO2009158120A3 (en)	2010-03-04
JP2011521974A (ja)	2011-07-28
WO2009158120A2 (en)	2009-12-30
CN102099020B (zh)	2013-09-18
BRPI0913214B1 (pt)	2022-05-17
AU2016202212B2 (en)	2018-05-10

Publication	Publication Date	Title
BRPI0913214A2 (pt)	2016-01-19	sistema de fornecimento de drogas transdérmico estabilizado
BRPI0917030A2 (pt)	2017-03-21	sistema de liberação de fármaco contendo progestina
BRPI0819245A2 (pt)	2016-07-19	sistema de distribuição transdérmica
BRPI0912144A2 (pt)	2015-11-03	configuração de sistema de infusão
BRPI0913008A2 (pt)	2015-10-13	dispositivo de administração de medicação
DK2185220T3 (da)	2019-06-17	Anordning til lægemiddelfremføring
BRPI0908231A2 (pt)	2015-07-21	Sistema de liberação de fármaco com efeito estabilizante
DK2274030T4 (da)	2020-06-08	Lægemiddelafgivelsesanordning
DK3756657T3 (da)	2025-06-02	Synkbar anordning til lægemiddelfremføring
DK2398500T3 (da)	2019-05-13	Glutathion-baseret lægemiddelafgivelsessystem
BRPI1010279A2 (pt)	2016-10-18	dispositivo de distribuição de fármaco
DK2355867T3 (da)	2014-09-08	Anordning til medikamentafgivelse
DK2274029T3 (da)	2012-02-27	Lægemiddelafgivelsesanordning
BR112013012818A2 (pt)	2016-08-23	módulo medicamentoso e sistema de administração de fármaco
BRPI1012730A2 (pt)	2016-05-03	dispositivo de distribuição de fármaco
BRPI0909653A2 (pt)	2015-09-22	sistema terapêutico transdérmico com membrama estabilizada
DK2296732T3 (da)	2014-04-07	Medikamentafgivelsesindretning
BRPI0920690A2 (pt)	2015-12-29	sistema de distribuição de stent restringível
DK2493532T3 (da)	2019-10-07	Lægemiddelfremføringsanordning
BRPI0920514A2 (pt)	2016-09-27	infusão de fármacos
BRPI1010237A2 (pt)	2016-10-18	dispositivo de distribuição de fármaco
BRPI1014975A2 (pt)	2016-04-26	sistema de entrega de implante
BRPI0813090A2 (pt)	2014-12-23	Sistema de injeção de autoadministração
DK2381988T3 (da)	2020-04-20	Medikamentadministrationsanordning
BRPI0923808A2 (pt)	2015-07-14	Controle eletrônico de sistema de distribuição de fármaco

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-31	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-02-26	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-10-22	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-12-31	B12B	Appeal against refusal [chapter 12.2 patent gazette]
2022-05-17	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.